Breaking News Instant updates and real-time market news.

WBA

Walgreens Boots Alliance

$65.35

1.14 (1.78%)

, KR

Kroger

$24.94

0.2 (0.81%)

06:47
05/17/18
05/17
06:47
05/17/18
06:47

Walgreen, Kroger, Albertsons, HEB sue Allergan over Restasis, Reuters reports

U.S. retailers Walgreens (WBA), Kroger (KR), Albertson's and HEB Grocery are suing Allergan (AGN) accusing the drugmaker of antitrust violations for trying to stop competitors from selling generic versions of its dry-eye treatment Restasis, Reuters reports, citing the suit. The retailers claim Allergan illegally preserved its monopoly by securing illegal patents, suing rivals that challenged those patents and transferring the patents to a sovereign Native American tribe, New York's Saint Regis Mohawk Tribe, to avoid scrutiny by U.S. courts. Reference Link

WBA

Walgreens Boots Alliance

$65.35

1.14 (1.78%)

KR

Kroger

$24.94

0.2 (0.81%)

AGN

Allergan

$154.46

2.32 (1.52%)

  • 17

    May

WBA Walgreens Boots Alliance
$65.35

1.14 (1.78%)

04/02/18
MSCO
04/02/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley says may make sense for Walmart to play bigger role in healthcare
Morgan Stanley analyst Simeon Gutman estimates Walmart (WMT) generates about $20B in pharmacy sales annually, which he believes makes it the third largest U.S. pharmacy provider behind CVS (CVS) and Walgreens (WBA). Following a report from The Wall Street Journal that the company and Humana (HUM) were in merger talks, and subsequent reports from Reuters and Bloomberg that the two may only be discussing a broader partnership instead of a buyout deal, Gutman said that consolidation of other retailers and healthcare providers could put Walmart at a disadvantage and he believes it may make sense for Walmart to play a larger role in healthcare. He maintains an Equal Weight rating on Walmart shares.
04/24/18
LEER
04/24/18
NO CHANGE
LEER
Amazon shelving pharma supply efforts to hospitals not surprising, says Leerink
Leerink analyst David Larsen notes that Amazon (AMZN) is said to be shelving its pharmaceutical supply efforts to hospitals, which he does not see as a suprise given several barriers to entry. The consumer market has always been Amazon's core competency, though he expects it will be a long, gradual, and difficult process of building up an online drug portfolio with an initial focus likely on generics. The analyst believes the risk of Amazon entering retail in the near term is reduced significantly. Nonetheless, Larsen thinks risk remains longer term for retail pharmacies such as CVS (CVS) and Walgreens Boots Alliance (WBA).
04/17/18
MZHO
04/17/18
NO CHANGE
MZHO
Amazon news removes 'unprecedented overhang' on drug sellers, says Mizuho
After CNBC reported yesterday afternoon that Amazon (AMZN) has decided to shelve its plan to sell and distribute pharmaceutical products, Mizuho analyst Ann Hynes said she had thought Amazon's current logistics and distribution model would not translate into healthcare. However, based on conversations with investors, she believes the magnitude of the overhang that Amazon presented for drug distributors and retail pharmacies was "unprecedented." While drug pricing is still a concern, she notes that the CNBC report removes one overhang on the drug supply chain stocks. Hynes remain a buyer of CVS Health (CVS) and Walgreens (WBA) and keeps Neutral ratings on Rite Aid (RAD) as well as on drug distributors AmerisourceBergen (ABC), Cardinal Health (CAH) and McKesson (MCK).
04/03/18
JEFF
04/03/18
NO CHANGE
Target $85
JEFF
Buy
Walgreens fundamentals to eventually drive shares higher, says Jefferies
Jefferies analyst Brian Tanquilut says that while Walgreens Boots Alliance shares will likely behave like a deal stock with an overhang that limits near-term upside, fundamentals will eventually drive the stock higher over the longer term. The analyst lowered his price target for Walgreens to $85 from $93 and keeps a Buy rating on the name. He expects continued earnings beats from the company, and thinks investors will eventually be rewarded.
KR Kroger
$24.94

0.2 (0.81%)

04/13/18
OPCO
04/13/18
NO CHANGE
OPCO
Outperform
Low levels of food inflation to keep weighing on grocery names, Oppenheimer says
Following a government report this week that showed another month of soft food inflation data, Oppenheimer analyst Rupesh Parikh said he expects low food inflation to continue to weigh on grocery names, taking a "subdued" view into earnings for pure-play grocery names like Kroger (KR), National Grocers (NGVC), Sprouts Farmers Market (SFM) and Smart & Final Stores (SFS). Parikh's top picks across the broader grocery/discounter space remain Dollar General (DG) and Dollar Tree (DLTR), followed by Sprouts, he said. The analyst has an Outperform rating on Dollar General, Dollar Tree and Sprouts, and a Perform rating on Kroger, Natural Grocers, Smart & Final Stores and United Natural Foods (UNFI).
04/17/18
FBCO
04/17/18
INITIATION
FBCO
Outperform
Kroger initiated with an Outperform at Credit Suisse
04/17/18
FBCO
04/17/18
INITIATION
FBCO
Outperform
Kroger initiated with an Outperform at Credit Suisse
Credit Suisse analyst Judah Frommer initiated Kroger with an Outperform and $28 price target, saying the company's underappreciated assets should drive above-consensus sales growth.
05/10/18
MOFT
05/10/18
DOWNGRADE
MOFT
Neutral
Kroger downgraded to Neutral from Buy at MoffettNathanson (pre-open)
AGN Allergan
$154.46

2.32 (1.52%)

05/01/18
DBAB
05/01/18
NO CHANGE
Target $210
DBAB
Buy
Deutsche continues to like the setup for Allergan shares
Deutsche Bank analyst Gregg Gilbert acknowledges the uncertainty regarding Allergan's strategic review but says he continues to like the setup for the shares. The analyst his earnings estimates based primarily on the Q1 outperformance and accelerated share repurchase. He keeps a Buy rating on Allergan with a $210 price target.
05/01/18
WELS
05/01/18
NO CHANGE
Target $240
WELS
Outperform
Allergan price target lowered to $240 from $245 at Wells Fargo
Wells Fargo analyst David Maris lowered his price target for Allergan to $240 from $245 following Q1 results and as investors seem to remain uncertain about Allergan's strategic direction. The analyst reiterates an Outperform rating on the shares.
05/07/18
CANT
05/07/18
NO CHANGE
CANT
Cantor positive on Evolus, Revance on potential to take Botox share
The potential launches of Evolus' (EOLS) DWP-450 in 2018 and Revance Therapeutics' (RVNC) RT002 in 2020 has investors wondering if less expensive and longer lasting toxins could take meaningful share away from Allergan's (AGN) Botox, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. After speaking with two physicians who use 500-864 vials of Botox per year in their practices, the analyst reiterates Overweight ratings on Evolus and Revance and a Neutral rating on Allergan. Both doctors, who use Allergan's Botox in 95%-plus of their patients, said they would switch a large amount of their practice over to less expensive and/or longer acting toxins, if they are approved, Chen writes.
05/16/18
WELS
05/16/18
NO CHANGE
WELS
Outperform
Evolus CRL good news for Allergan, says Wells Fargo
Wells Fargo analyst David Maris noted that Evolus (EOLS) received a Complete Response Letter for its application for cosmetic neuro toxin candidate DWP-450, which he views as good news for Allergan (AGN) as the delay means Evolus will miss the 2018-2019 holiday season, which he points out is an important selling season for Botox. Maris, who also thinks Allergan may be able to use the CRL to "counter-detail" DWP-450 with doctors if the product does reach market, keeps an Outperform rating on Allergan shares.

TODAY'S FREE FLY STORIES

15:10
08/21/18
08/21
15:10
08/21/18
15:10
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

PSTG

Pure Storage

$22.00

0.2 (0.92%)

15:04
08/21/18
08/21
15:04
08/21/18
15:04
Options
Pure Storage options imply 10.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 04

    Sep

  • 12

    Sep

  • 03

    Oct

  • 04

    Oct

  • 05

    Oct

CASY

Casey's General Stores

$116.05

1.33 (1.16%)

15:01
08/21/18
08/21
15:01
08/21/18
15:01
Conference/Events
Casey's General Stores management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 17

    Sep

  • 06

    Nov

RIGL

Rigel Pharmaceuticals

$2.67

0.08 (3.09%)

15:00
08/21/18
08/21
15:00
08/21/18
15:00
Hot Stocks
Rigel's Rodriguez says 'work has just begun' with Tavalisse launch »

In an exclusive interview…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EA

Electronic Arts

$127.21

-0.47 (-0.37%)

15:00
08/21/18
08/21
15:00
08/21/18
15:00
Options
Electronic Arts attracts a bullish option play »

Electronic Arts attracts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 04

    Sep

  • 12

    Sep

  • 12

    Sep

  • 13

    Sep

URBN

Urban Outfitters

$47.40

-0.12 (-0.25%)

14:49
08/21/18
08/21
14:49
08/21/18
14:49
Options
Urban Outfitters options imply 12.9% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

SFIX

Stitch Fix

$34.77

1.92 (5.84%)

14:45
08/21/18
08/21
14:45
08/21/18
14:45
Options
Stitch Fix call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 01

    Oct

ATVI

Activision Blizzard

$69.63

0.7 (1.02%)

14:40
08/21/18
08/21
14:40
08/21/18
14:40
Periodicals
Breaking Periodicals news story on Activision Blizzard »

M Science says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 04

    Sep

  • 12

    Sep

  • 13

    Sep

NURO

NeuroMetrix

$1.26

0.04 (3.28%)

, GSK

GlaxoSmithKline

$41.57

0.25 (0.61%)

14:32
08/21/18
08/21
14:32
08/21/18
14:32
Hot Stocks
NeuroMetrix receives $3.8M milestone payment under its pact with GSK »

NeuroMetrix (NURO)…

NURO

NeuroMetrix

$1.26

0.04 (3.28%)

GSK

GlaxoSmithKline

$41.57

0.25 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Aug

14:30
08/21/18
08/21
14:30
08/21/18
14:30
General news
Canada Retail Sales Preview »

Canada Retail Sales…

14:25
08/21/18
08/21
14:25
08/21/18
14:25
General news
Treasury Option Action: more bond positioning »

Treasury Option Action:…

MDT

Medtronic

$95.02

4.96 (5.51%)

14:20
08/21/18
08/21
14:20
08/21/18
14:20
Recommendations
Medtronic analyst commentary  »

Medtronic momentum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 23

    Aug

  • 05

    Sep

  • 12

    Sep

MS

Morgan Stanley

$48.75

0.48 (0.99%)

14:20
08/21/18
08/21
14:20
08/21/18
14:20
Options
Mega option block in Morgan Stanley »

Mega option block in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
08/21/18
08/21
14:17
08/21/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIGL

Rigel Pharmaceuticals

$2.65

0.06 (2.32%)

14:16
08/21/18
08/21
14:16
08/21/18
14:16
Hot Stocks
Rigel CEO says impact of any Trump policy still unclear »

In an exclusive interview…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
08/21/18
08/21
14:16
08/21/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$339.67

11.92 (3.64%)

, AAPL

Apple

$216.73

1.25 (0.58%)

14:07
08/21/18
08/21
14:07
08/21/18
14:07
Periodicals
Netflix testing how to bypass iTunes billing in 33 countries, TechCrunch says »

Netflix (NFLX) is…

NFLX

Netflix

$339.67

11.92 (3.64%)

AAPL

Apple

$216.73

1.25 (0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

UAL

United Continental

$86.00

0.765 (0.90%)

14:06
08/21/18
08/21
14:06
08/21/18
14:06
Periodicals
United's Kirby sees average airfares improving, Bloomberg reports »

As U.S. rivals offer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

APO

Apollo Global

$34.44

0.22 (0.64%)

, BX

Blackstone

$36.48

-0.32 (-0.87%)

14:04
08/21/18
08/21
14:04
08/21/18
14:04
Periodicals
PE firms eyeing acquisitions of local TV assets, CNBC reports »

Apollo Global (APO),…

APO

Apollo Global

$34.44

0.22 (0.64%)

BX

Blackstone

$36.48

-0.32 (-0.87%)

NXST

Nexstar

$80.25

1.05 (1.33%)

TRCO

Tribune Media

$35.98

0.91 (2.59%)

SBGI

Sinclair Broadcast

$29.30

0.55 (1.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 06

    Sep

UAL

United Continental

$86.32

1.085 (1.27%)

14:00
08/21/18
08/21
14:00
08/21/18
14:00
Options
Heavy call activity in UAL as shares take off »

Heavy call activity in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

RIGL

Rigel Pharmaceuticals

$2.66

0.07 (2.70%)

13:52
08/21/18
08/21
13:52
08/21/18
13:52
Hot Stocks
Rigel's Rodriguez says physician response to Tavalisse 'very positive' »

In an exclusive interview…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JCI

Johnson Controls

$39.84

1.11 (2.87%)

13:50
08/21/18
08/21
13:50
08/21/18
13:50
Options
Notable call spread in Johnson Controls as shares rally »

Notable call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$287.20

1.52 (0.53%)

, SPX

S&P 500

$0.00

(0.00%)

13:46
08/21/18
08/21
13:46
08/21/18
13:46
Periodicals
Michael Cohen enters plea deal with federal prosecutors, ABC News says »

Tom Llamas, ABC…

SPY

SPDR S&P 500 ETF Trust

$287.20

1.52 (0.53%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GME

GameStop

$16.35

0.5 (3.15%)

13:45
08/21/18
08/21
13:45
08/21/18
13:45
Options
GameStop call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:40
08/21/18
08/21
13:40
08/21/18
13:40
General news
FOMC minutes preview: »

FOMC minutes preview: the…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.